Current and future burden of breast cancer: Global statistics for 2020 and 2040

Arnold, Melina; Morgan, Eileen; Rumgay, Harriet; Costa, Allini Mafra da; Singh, Deependra; Laversanne, Mathieu; Vignat, Jérôme; Gralow, Julie R.; Cardoso, Fátima; Siesling, Sabine; Soerjomataram, Isabelle

doi:10.1016/j.breast.2022.08.010

Cited by 1,067 publications

(723 citation statements)

References 37 publications

Supporting

Mentioning

473

Contrasting

Unclassified

Order By: Relevance

“…Almost 80% of breast cancer patients belong to the Luminal A (ER+ and/or PR+, HER2−) and Luminal B (ER+ and/or PR+, HER2+) subgroups, which highlight the major role of the hormonal receptors in this disease [ 5 ]. In 2020, breast cancer ranked as the most commonly diagnosed cancer among 36 cancer types and it surpassed lung cancer in 185 countries [ 6 ] with a total of 2.3 million new cases, which represent 11.7% of total cancers worldwide [ 7 ]. Despite the huge progress in breast cancer management and the development of several novel targeted therapies, the number of breast-cancer-related deaths remains large, with almost 685,000 deaths in 2020, which correspond to 16% of cancer deaths in women, and the number is predicted to increase to more than 1 million deaths per year by 2040 [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Targeting Adiponectin in Breast Cancer

et al. 2022

View full text Add to dashboard Cite

Obesity and breast cancer are two major health issues that could be categorized as sincere threats to human health. In the last few decades, the relationship between obesity and cancer has been well established and extensively investigated. There is strong evidence that overweight and obesity increase the risk of postmenopausal breast cancer, and adipokines are the central players in this relationship. Produced and secreted predominantly by white adipose tissue, adiponectin is a bioactive molecule that exhibits numerous protective effects and is considered the guardian angel of adipokine. In the obesity–cancer relationship, more and more evidence shows that adiponectin may prevent and protect individuals from developing breast cancer. Recently, several updates have been published on the implication of adiponectin in regulating tumor development, progression, and metastases. In this review, we provide an updated overview of the metabolic signaling linking adiponectin and breast cancer in all its stages. On the other hand, we critically summarize all the available promising candidates that may reactivate these pathways mainly by targeting adiponectin receptors. These molecules could be synthetic small molecules or plant-based proteins. Interestingly, the advances in genomics have made it possible to create peptide sequences that could specifically replace human adiponectin, activate its receptor, and mimic its function. Thus, the obvious anti-cancer activity of adiponectin on breast cancer should be better exploited, and adiponectin must be regarded as a serious biomarker that should be targeted in order to confront this threatening disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeting Adiponectin in Breast Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Triple-Negative Breast Cancers (TNBC) characteristically lack, or express at very low levels, human growth factor receptor 2 (HER2), progesterone (PR) and/or estrogen receptors (ER) ( 1 ). In 2020, 12% -17% of the 2.3 million new breast cancer (BC) cases and over 685,000 deaths worldwide can be attributed to TNBC ( 2 ). TNBC disproportionally affects young premenopausal women with west African ancestry, particularly African American and Ghanaian women ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

Understanding and harnessing triple-negative breast cancer-related microbiota in oncology

2022

View full text Add to dashboard Cite

Bacterial inhabitants of the body have the potential to play a role in various stages of cancer initiation, progression, and treatment. These bacteria may be distal to the primary tumour, such as gut microbiota, or local to the tissue, before or after tumour growth. Breast cancer is well studied in this context. Amongst breast cancer types, Triple Negative Breast Cancer (TNBC) is more aggressive, has fewer treatment options than receptor-positive breast cancers, has an overall worse prognosis and higher rates of reoccurrence. Thus, an in-depth understanding of the bacterial influence on TNBC progression and treatment is of high value. In this regard, the Gut Microbiota (GM) can be involved in various stages of tumour progression. It may suppress or promote carcinogenesis through the release of carcinogenic metabolites, sustenance of proinflammatory environments and/or the promotion of epigenetic changes in our genome. It can also mediate metastasis and reoccurrence through interactions with the immune system and has been recently shown to influence chemo-, radio-, and immune-therapies. Furthermore, bacteria have also been found to reside in normal and malignant breast tissue. Several studies have now described the breast and breast tumour microbiome, with the tumour microbiota of TNBC having the least taxonomic diversity among all breast cancer types. Here, specific conditions of the tumour microenvironment (TME) - low O2, leaky vasculature and immune suppression - are supportive of tumour selective bacterial growth. This innate bacterial ability could enable their use as delivery agents for various therapeutics or as diagnostics. This review aims to examine the current knowledge on bacterial relevance to TNBC and potential uses while examining some of the remaining unanswered questions regarding mechanisms underpinning observed effects.

show abstract

“…Breast cancer is the most commonly diagnosed cancer among women worldwide [ 1 ]. The majority of women, particularly those living in high-income countries diagnosed with early-stage disease [ 2 ], can expect a good prognosis.…”

Section: Introductionmentioning

confidence: 99%

Do Patient-Reported Upper-Body Symptoms Predict Breast Cancer-Related Lymphoedema: Results from a Population-Based, Longitudinal Breast Cancer Cohort Study

Hayes

Dunn

Plinsinga

et al. 2022

Cancers

View full text Add to dashboard Cite

The objectives of this work were to (i) describe upper-body symptoms post-breast cancer; (ii) explore the relationship between symptoms and upper-body function, breast cancer-related lymphoedema (BCRL), physical activity levels, and quality of life; and (iii) determine whether the presence of upper-body symptoms predicts BCRL. Nine symptoms, upper-body function, lymphoedema, physical activity, and quality of life were assessed in women with invasive breast cancer at baseline (2- to 9-months post-diagnosis; n = 2442), and at 2- and 7-years post-diagnosis. Mann–Whitney tests, unpaired t-tests, and chi-squared analyses were used to assess cross-sectional relationships, while regression analyses were used to assess the predictive relationships between symptoms at baseline, and BCRL at 2- and 7-years post-diagnosis. Symptoms are common post-breast cancer and persist at 2- and 7-years post-diagnosis. Approximately two in three women, and one in three women, reported >2 symptoms of at least mild severity, and of at least moderate severity, respectively. The presence of symptoms is associated with poorer upper-body function, and lower physical activity levels and quality of life. One or more symptoms of at least moderate severity increases the odds of developing BCRL by 2- and 7-years post-diagnosis (p < 0.05). Consequently, improved monitoring and management of symptoms following breast cancer have the potential to improve health outcomes.

show abstract

Current and future burden of breast cancer: Global statistics for 2020 and 2040

Cited by 1,067 publications

References 37 publications

Targeting Adiponectin in Breast Cancer

Targeting Adiponectin in Breast Cancer

Understanding and harnessing triple-negative breast cancer-related microbiota in oncology

Do Patient-Reported Upper-Body Symptoms Predict Breast Cancer-Related Lymphoedema: Results from a Population-Based, Longitudinal Breast Cancer Cohort Study

Contact Info

Product

Resources

About